The emerging innovative drugs include mAbs targeting on characteristic pathways of type 2 inflammation, such as those of IgE, the IL-5, and IL-4/IL-13 which are involved in several pathologic condictions including CRSwNP or allergic rhinitis. Here, IL13 is linked to chronic rhinosinusitis with nasal polyps.